Celcuity, Inc. $CELC Shares Sold by Simplicity Wealth LLC

Simplicity Wealth LLC lessened its position in Celcuity, Inc. (NASDAQ:CELC) by 95.7% during the third quarter, Holdings Channel reports. The institutional investor owned 4,671 shares of the company’s stock after selling 104,812 shares during the quarter. Simplicity Wealth LLC’s holdings in Celcuity were worth $371,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CELC. Assenagon Asset Management S.A. boosted its stake in Celcuity by 685.9% during the third quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company’s stock valued at $117,579,000 after buying an additional 1,290,466 shares in the last quarter. Bank of America Corp DE bought a new stake in Celcuity in the second quarter worth about $153,928,000. Wellington Management Group LLP raised its position in Celcuity by 111.4% in the second quarter. Wellington Management Group LLP now owns 906,595 shares of the company’s stock worth $94,848,000 after acquiring an additional 477,643 shares in the last quarter. Jennison Associates LLC raised its position in Celcuity by 0.6% in the first quarter. Jennison Associates LLC now owns 231,140 shares of the company’s stock worth $26,382,000 after acquiring an additional 1,436 shares in the last quarter. Finally, Alyeska Investment Group L.P. lifted its holdings in Celcuity by 127.2% in the 2nd quarter. Alyeska Investment Group L.P. now owns 170,846 shares of the company’s stock valued at $17,874,000 after acquiring an additional 95,664 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Stock Down 0.2%

CELC stock opened at $69.13 on Friday. The firm has a market capitalization of $3.38 billion, a P/E ratio of -16.08 and a beta of 0.10. The company’s 50 day simple moving average is $77.67 and its 200-day simple moving average is $100.37. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity, Inc. has a 52-week low of $53.54 and a 52-week high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). As a group, equities research analysts anticipate that Celcuity, Inc. will post -4.98 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CELC shares. Citigroup restated a “market outperform” rating on shares of Celcuity in a research report on Monday, October 19th. TD Cowen reiterated a “buy” rating and issued a $145.00 target price on shares of Celcuity in a report on Wednesday, October 21st. Royal Bank Of Canada lowered shares of Celcuity to a “neutral” rating in a research note on Wednesday. Craig Hallum restated a “buy” rating and set a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Finally, HC Wainwright restated a “buy” rating and issued a $155.00 price target on shares of Celcuity in a research report on Friday, August 14th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $152.57.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.